Pharmaceuticals Biotechnology and Life Sciences

More

• UPDATE 2-Roche flags further growth as new drugs deliver

  *To pay 7.35 Sfr per share dividend for 2012. BASEL, Jan 30- Swiss drugmaker Roche forecast a rise in sales and profits this year, helped by new cancer medicines it hopes will shield it from the patent expiries ravaging many rivals.

• Roche CEO: Emerging Markets Key to Momentum

  

  Emerging markets, and in particular, Latin America will be the drivers for continued growth, Swiss drug maker Roche told CNBC, even as the company faces price pressures elsewhere.

• FDA gives new drug application approval to Isis

  CARLSBAD, Calif.-- Drug developer Isis Pharmaceuticals Inc. and partner Genzyme announced Tuesday that the U.S. Food and Drug Administration has approved their new drug application for Kynamro, clearing the way for Isis' first drug to reach market.

• Vertex swings to loss on weak hep C drug sales

  CAMBRIDGE, Mass.-- Specialty drugmaker Vertex Pharmaceuticals Inc. swung to a loss in the fourth quarter as doctors turned away from the company's best-selling drug for treating hepatitis C. Most of the decline was due to lower sales of the company's hepatitis C pill, Incivek, which contributed $223 million, down from $457 million.

• UPDATE 1-FDA approves Sanofi drug for rare cholesterol disorder

  *Drug from Sanofi and Isis Pharmaceuticals to be sold as Kynamro. *FDA requiring four post-marketing studies. Jan 29- The U.S. Food and Drug Administration on Tuesday approved a drug made by Sanofi SA and Isis Pharmaceuticals Inc designed to treat a rare genetic disorder that causes dangerously high levels of bad LDL cholesterol.

• FDA approves Sanofi drug for hereditary cholesterol disorder

  *Drug from Sanofi and Isis Pharmaceuticals to be sold as Kynamro. *FDA requiring four post-marketing studies. Jan 29- The U.S. Food and Drug Administration on Tuesday approved a drug made by Sanofi SA and Isis Pharmaceuticals Inc designed to treat a rare genetic disorder that causes dangerously high levels of bad LDL cholesterol.

• Keryx announces $55M public offering

  NEW YORK-- Keryx Biopharmaceuticals Inc. said Tuesday that it will offer $55 million worth of its common stock in a public offering. The company plans to submit an application for approval of the drug to both the U.S. Food and Drug Administration and European regulators in this year's second quarter.

• WRAPUP 2-Pfizer, Lilly profits beat Street; generics take toll

  Jan 29- Pfizer Inc and Eli Lilly and Co reported better-than-expected fourth-quarter profits as deals, cost cutting and strong sales of new products helped the pharmaceutical companies weather generic competition for once top-selling products.

• Keryx shares keep climbing on drug trial results

  Shares of Keryx Biopharmaceuticals Inc. extended its gains Tuesday, a day after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.

• Anacor shares sink after release of study results

  Shares of Anacor Pharmaceuticals Inc. plunged Tuesday after the drug developer said its potential nail fungus treatment did better than a placebo in a late stage study, but an analyst said it fared poorly compared to a rival's product.

• UPDATE 3-Lilly says generic competition hurts Q4 profit, sales

  *R&D tax credit to add 7 cents to 2013 EPS. The U.S. drugmaker earned $827 million, or 74 cents per share, down from $858 million, or 77 cents per share, a year earlier. Excluding special items such as asset impairments and restructuring, Lilly earned 85 cents per share, beating analysts' expectations by 7 cents per share.

• UPDATE 1-Pfizer Q4 results top forecast, gives cautious 2013 view

  Jan 29- Pfizer Inc on Tuesday reported better-than-expected fourth-quarter results, helped by rebounding sales in emerging markets, but the drugmaker forecast earnings for 2013 that was mostly below consensus analyst expectations.

• UPDATE 2-Lilly says generic competition hurts profit, sales

  Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter profit fell as competition from generic drugs, particularly for its once top-selling schizophrenia drug Zyprexa, drove revenue lower. The U.S. drugmaker earned $827 million, or 74 cents per share, down from $858 million, or 77 cents per share, a year earlier.

• UPDATE 1-Lilly loses ground in fourth quarter to generics

  Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter earnings fell as competition from generic drugs, particularly for its top-selling schizophrenia drug Zyprexa, drove revenue lower. The U.S. drugmaker earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.

• Lilly fourth-quarter profit fall as generics hurt sales

  Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter earnings had fallen as competition from generic drugs drove revenue lower. The U.S. drugmaker said it had earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.

• WRAPUP 1-Pfizer, Lilly beat Street; generics take toll

  Jan 29- Pfizer Inc and Eli Lilly and Co both reported a better-than-expected fourth-quarter profit as they weathered generic competition for once top-selling products through deals, cost cutting and strong sales of newer products.

• ImmunoGen slides as analyst cuts rating

  NEW YORK-- ImmunoGen slipped 3 percent in Monday trading as Oppenheimer lowered its rating on the cancer drug developer, noting rapid gains in the company's share price over the last few months. THE SPARK: Oppenheimer& Co. analyst Boris Peaker downgraded the stock to "Perform" from "Outperform."

• Furiex jumps after diabetes drug approval

  NEW YORK-- Shares of Furiex Pharmaceuticals Inc. surged Monday after regulators approved three new diabetes drugs that Japanese drugmaker Takeda developed with help from Furiex. THE SPARK: On Friday, Takeda said the Food and Drug Administration approved the type 2 diabetes drug Nesina and the combination drugs Oseni and Kazano.

• FDA accepts application for new Sanofi MS drug

  NEW YORK-- French drugmaker Sanofi said Monday that the Food and Drug Administration will review its experimental multiple sclerosis treatment Lemtrada.

• Keryx shares soar on kidney drug results

  NEW YORK-- Shares of Keryx Biopharmaceuticals Inc. soared Monday after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.